Mouse BTLA Antibody

Detection of Mouse BTLA by Western Blot. Western blot shows lysates of mouse spleen tissue and mouse lymph node tissue. PVDF membrane was probed with 1 µg/mL of Goat Anti-Mouse BTLA Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3007) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for BTLA at approximately 60 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Detection of Human BTLA/CD272 by Western Blot Activation of PPAR beta /δ results in upregulation of FABP5. (a) PC3M cells were treated with GW0742 (1 μM, 4 h). Expression of FABP5, PDK1, ADRP, and VEGF were assessed by Q-PCR. The data were normalized to the untreated control. (b, c) Denoted cells were treated with 1 μM (a) or 2 μM (b) GW0742 for 16 h. Left panels, immunoblots of FABP5 in untreated versus GW0742-treated cells. Right panel: Densitometry analyses depicting changes in FABP5 expression upon treatment with GW0742 in three independent experiments (mean ± S.D.). (d, e) PC3M cells were transfected with vectors harboring SiScramble or PPAR beta /δ siRNA. Three days later, expression of FABP5, PPAR beta /δ, and VEGF mRNA in were measured by Q-PCR (d) and FABP5 expression was assessed by immunoblot (e). (f) PC3M cells were stably transfected with an empty vector (PGIPZ), or a vector harbouring shFABP5. Expression levels of FABP5, PPAR beta /δ, and VEGF mRNA were measured by Q-PCR. *P <.05 versus nontreated controls. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/20847935), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human BTLA/CD272 by Western Blot Prostate cancer progression is accompanied by up regulation of FABP5/PPAR beta /δ expression and signalling. (a) Bottom: Expression levels of FABP5 mRNA in denoted cell lines were measured by Q-PCR. Top: Level of FABP5 protein in denoted cell lines assessed by immunoblots. (b) Bottom: Expression levels of PDK-1 and PPAR beta /δ mRNA in denoted cell lines were measured by Q-PCR. Top: Immunoblots of PDK1 in denoted cell lines. Data are mean ± S.D. (n = 3). *P <.02 versus 22Rv.1. (Paired T test). Immunoblots were repeated three times with similar results. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/20847935), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human BTLA/CD272 by Western Blot Activation of PPAR beta /δ results in upregulation of FABP5. (a) PC3M cells were treated with GW0742 (1 μM, 4 h). Expression of FABP5, PDK1, ADRP, and VEGF were assessed by Q-PCR. The data were normalized to the untreated control. (b, c) Denoted cells were treated with 1 μM (a) or 2 μM (b) GW0742 for 16 h. Left panels, immunoblots of FABP5 in untreated versus GW0742-treated cells. Right panel: Densitometry analyses depicting changes in FABP5 expression upon treatment with GW0742 in three independent experiments (mean ± S.D.). (d, e) PC3M cells were transfected with vectors harboring SiScramble or PPAR beta /δ siRNA. Three days later, expression of FABP5, PPAR beta /δ, and VEGF mRNA in were measured by Q-PCR (d) and FABP5 expression was assessed by immunoblot (e). (f) PC3M cells were stably transfected with an empty vector (PGIPZ), or a vector harbouring shFABP5. Expression levels of FABP5, PPAR beta /δ, and VEGF mRNA were measured by Q-PCR. *P <.05 versus nontreated controls. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/20847935), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human BTLA/CD272 by Western Blot The FABP5/PPAR beta /δ pathway enhances prostate cancer cell proliferation and transformation. (a) PC3M cells that stably express shFABP5 were cultured in a 24 well plate (2500 cells/well) and treated with vehicle or GW 0742 (1 μM). Cells were counted at the denoted days. Data are mean ± SEM (n = 3). Inset: immunoblotting demonstrating low FABP5 level in shFABP5-expressing. (b) PC3M cells were transfected with a vector harboring PPAR beta /δsiRNA. Four days later, were cultured in a 24 well plate (2500 cells/well) and treated with vehicle or GW 0742 (1 μM). Cells were counted at the denoted days. Inset: Q-PCR analyses demonstrating low PPAR beta /δ in cells transfected with SiRNA towards the receptor. (c) Colony formation assays were conducted in the absence or presence of GW0742 (1 μM). Cells were cultured in 2% agarose for 29 days (see Materials and methods for details). Media was replenished every 4 days. Colonies were visualized by staining with 0.005% crystal violet and counted under a light microscope. Data are mean ± SEM (n = 3). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/20847935), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human BTLA/CD272 by Western Blot Activation of PPAR beta /δ results in upregulation of FABP5. (a) PC3M cells were treated with GW0742 (1 μM, 4 h). Expression of FABP5, PDK1, ADRP, and VEGF were assessed by Q-PCR. The data were normalized to the untreated control. (b, c) Denoted cells were treated with 1 μM (a) or 2 μM (b) GW0742 for 16 h. Left panels, immunoblots of FABP5 in untreated versus GW0742-treated cells. Right panel: Densitometry analyses depicting changes in FABP5 expression upon treatment with GW0742 in three independent experiments (mean ± S.D.). (d, e) PC3M cells were transfected with vectors harboring SiScramble or PPAR beta /δ siRNA. Three days later, expression of FABP5, PPAR beta /δ, and VEGF mRNA in were measured by Q-PCR (d) and FABP5 expression was assessed by immunoblot (e). (f) PC3M cells were stably transfected with an empty vector (PGIPZ), or a vector harbouring shFABP5. Expression levels of FABP5, PPAR beta /δ, and VEGF mRNA were measured by Q-PCR. *P <.05 versus nontreated controls. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/20847935), licensed under a CC-BY license. Not internally tested by R&D Systems.